Anti-tumor necrosis factor antibody reduces mortality in the presence of antibiotic-induced tumor necrosis factor release

Arch Surg. 1993 Jan;128(1):73-7; discussion 77-8. doi: 10.1001/archsurg.1993.01420130081013.

Abstract

The systemic tumor necrosis factor (TNF) response has been extensively studied during infection. In addition, antibiotics that cause cell-wall lysis have been associated with endotoxinemia and, therefore, could trigger TNF release. We studied the effects of pretreatment with cefoxitin and/or anti-TNF antibody on mortality and early (90 minutes) and delayed (6 hours) serum TNF levels in a murine model of mixed Escherichia coli/Bacteroides fragilis peritonitis. At low and intermediate inocula levels, cefoxitin, but not anti-TNF antibody, prevented death, and low serum TNF levels were noted in all groups. At the highest inoculum level, mortality was uniform in control, cefoxitin, and anti-TNF antibody groups, and a significant elevation in serum TNF levels was seen only at the 6-hour point in animals receiving cefoxitin. The addition of anti-TNF antibody to cefoxitin at this inoculum level abrogated the 6-hour rise in serum TNF levels and reduced mortality to 40%. These results emphasize that the cytokine response in disease is dependent on both the nature of the insult and other forms of therapeutic interventions.

Publication types

  • Comparative Study
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Antibodies, Anti-Idiotypic / administration & dosage
  • Antibodies, Anti-Idiotypic / pharmacology
  • Antibodies, Anti-Idiotypic / therapeutic use*
  • Bacteroides Infections / blood
  • Bacteroides Infections / drug therapy*
  • Bacteroides Infections / mortality
  • Bacteroides fragilis*
  • Cefoxitin / administration & dosage
  • Cefoxitin / pharmacology
  • Cefoxitin / therapeutic use*
  • Disease Models, Animal
  • Drug Evaluation, Preclinical
  • Drug Therapy, Combination
  • Escherichia coli Infections / blood
  • Escherichia coli Infections / drug therapy*
  • Escherichia coli Infections / mortality
  • Immunoglobulin G*
  • Injections, Intramuscular
  • Injections, Intraperitoneal
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Peritonitis / blood
  • Peritonitis / drug therapy*
  • Peritonitis / mortality
  • Survival Rate
  • Tumor Necrosis Factor-alpha / chemistry
  • Tumor Necrosis Factor-alpha / drug effects*
  • Tumor Necrosis Factor-alpha / immunology

Substances

  • Antibodies, Anti-Idiotypic
  • Immunoglobulin G
  • Tumor Necrosis Factor-alpha
  • Cefoxitin